AR114990A1 - Constructos de oligonucleótidos y usos de los mismos - Google Patents
Constructos de oligonucleótidos y usos de los mismosInfo
- Publication number
- AR114990A1 AR114990A1 ARP180103199A ARP180103199A AR114990A1 AR 114990 A1 AR114990 A1 AR 114990A1 AR P180103199 A ARP180103199 A AR P180103199A AR P180103199 A ARP180103199 A AR P180103199A AR 114990 A1 AR114990 A1 AR 114990A1
- Authority
- AR
- Argentina
- Prior art keywords
- cpg odn
- group
- formula
- cpg
- tlr9
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6025—Nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen agonistas del receptor de tipo toll 9 (TLR9) inmunoestimuladores basados en oligodesoxinucleótidos. También se describen composiciones que comprenden los agonistas de TLR9, métodos para elaborar los agonistas de TLR9 y métodos para usar los agonistas de TLR9 para tratar enfermedades, trastornos o afecciones inmunes, tales como infecciones virales o cáncer. Reivindicación 1: Un constructo de ODN de CpG que tiene una fórmula de: fórmula (1): 5 M-L-[CpG ODN] 3, o fórmula (2): 5 [CpG ODN]-L-M 3 en donde: M representa una entidad lipídica, preferentemente la entidad lipídica comprende al menos una entidad lipídica seleccionada del grupo que consiste en colesterol, tocoferol, un grupo palmitoilo, y un grupo estearilo; L representa un conector que comprende 10 - 100 átomos seleccionados del grupo que consiste en carbono, nitrógeno, oxígeno, hidrógeno, azufre y fósforo, en donde L está unido covalentemente al ODN de CpG mediante un enlace escindible, preferentemente mediante una unión éster o amida; y el ODN de CpG comprende al menos un motivo de CpG que tiene un enlace internucleótido po, preferentemente, comprende al menos dos, tres o cuatro motivos de CpG, cada uno con el enlace internucleótido po; opcionalmente, el constructo de ODN de CpG de la fórmula (1) ó (2) se conjuga aún más covalentemente con una entidad objetivo, que se selecciona preferentemente del grupo que consiste en galactosa, N-acetilgalactosamina (GalNAc), fucosa, manosa, ácido siálico, ácido N-acetil neuramínico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762580924P | 2017-11-02 | 2017-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR114990A1 true AR114990A1 (es) | 2020-11-18 |
Family
ID=64901014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180103199A AR114990A1 (es) | 2017-11-02 | 2018-11-02 | Constructos de oligonucleótidos y usos de los mismos |
Country Status (14)
Country | Link |
---|---|
US (2) | US10905767B2 (es) |
EP (2) | EP4123034A1 (es) |
JP (1) | JP2021512044A (es) |
KR (1) | KR20200084004A (es) |
CN (1) | CN111601900A (es) |
AR (1) | AR114990A1 (es) |
AU (1) | AU2018362008A1 (es) |
BR (1) | BR112020008546A2 (es) |
CA (1) | CA3079157A1 (es) |
ES (1) | ES2960535T3 (es) |
MX (1) | MX2020004600A (es) |
RU (1) | RU2020117611A (es) |
TW (1) | TW201932596A (es) |
WO (1) | WO2019087144A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
US20220259254A1 (en) | 2019-07-05 | 2022-08-18 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
WO2021064614A1 (en) * | 2019-09-30 | 2021-04-08 | Janssen Biopharma, Inc. | Toll-like receptor 7 and/or 8 agonists and uses thereof |
WO2022032191A1 (en) | 2020-08-07 | 2022-02-10 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
WO2022034555A1 (en) * | 2020-08-13 | 2022-02-17 | Janssen Biopharma, Inc. | Polynucleotide constructs and uses thereof |
CN113499433B (zh) * | 2021-06-21 | 2022-03-18 | 复旦大学 | 一种具有抗肿瘤活性的GalNAc/CpG脂质体疫苗、制备方法及应用 |
CN114573652A (zh) * | 2022-03-15 | 2022-06-03 | 通用生物(滁州)有限公司 | 药用核酸合成工艺 |
CN114591387A (zh) * | 2022-03-21 | 2022-06-07 | 通用生物(滁州)有限公司 | 一种药用核酸合成后的胺洗工艺 |
WO2024110843A1 (en) * | 2022-11-21 | 2024-05-30 | Segena Corporation S.A. | Enhancing oligonucleotide immunomodulatory activity through dianophore long-lasting modification: methods and applications |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
US10100316B2 (en) * | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
JP4989225B2 (ja) * | 2003-09-25 | 2012-08-01 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 核酸親油性接合体 |
DE102006007433A1 (de) * | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure |
EP2162117B1 (en) * | 2007-05-31 | 2018-02-21 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
DE102009039097B3 (de) | 2009-08-27 | 2010-11-25 | Siemens Aktiengesellschaft | Verfahren zum Übertragen von Daten in einem Sensornetzwerk, Sensorknoten und Zentral-Rechner |
WO2012005769A1 (en) | 2010-07-09 | 2012-01-12 | Telecommunication Systems, Inc. | Location privacy selector |
ES2731524T3 (es) * | 2012-04-05 | 2019-11-15 | Massachusetts Inst Technology | Composiciones inmunoestimuladoras y métodos de uso de las mismas |
CA2871490C (en) * | 2012-04-27 | 2022-10-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cpg oligonucleotides co-formulated with an antibiotic to accelerate wound healing |
EP3076918A4 (en) * | 2013-12-03 | 2017-06-07 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
ES2725948T3 (es) * | 2014-06-04 | 2019-09-30 | Exicure Inc | Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas |
JP6611298B2 (ja) * | 2017-03-29 | 2019-11-27 | 塩野義製薬株式会社 | 免疫賦活活性を有する核酸誘導体 |
-
2018
- 2018-11-02 KR KR1020207015400A patent/KR20200084004A/ko not_active Application Discontinuation
- 2018-11-02 WO PCT/IB2018/058628 patent/WO2019087144A1/en unknown
- 2018-11-02 EP EP22179021.5A patent/EP4123034A1/en active Pending
- 2018-11-02 RU RU2020117611A patent/RU2020117611A/ru unknown
- 2018-11-02 US US16/179,786 patent/US10905767B2/en active Active
- 2018-11-02 ES ES18826793T patent/ES2960535T3/es active Active
- 2018-11-02 AU AU2018362008A patent/AU2018362008A1/en active Pending
- 2018-11-02 MX MX2020004600A patent/MX2020004600A/es unknown
- 2018-11-02 TW TW107139027A patent/TW201932596A/zh unknown
- 2018-11-02 CN CN201880071398.4A patent/CN111601900A/zh active Pending
- 2018-11-02 EP EP18826793.4A patent/EP3704269B1/en active Active
- 2018-11-02 BR BR112020008546-4A patent/BR112020008546A2/pt unknown
- 2018-11-02 CA CA3079157A patent/CA3079157A1/en active Pending
- 2018-11-02 JP JP2020524265A patent/JP2021512044A/ja active Pending
- 2018-11-02 AR ARP180103199A patent/AR114990A1/es unknown
-
2021
- 2021-01-05 US US17/142,192 patent/US20210196831A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3704269A1 (en) | 2020-09-09 |
WO2019087144A1 (en) | 2019-05-09 |
ES2960535T3 (es) | 2024-03-05 |
MX2020004600A (es) | 2020-10-05 |
EP3704269C0 (en) | 2023-08-30 |
TW201932596A (zh) | 2019-08-16 |
US10905767B2 (en) | 2021-02-02 |
US20190160173A1 (en) | 2019-05-30 |
CN111601900A (zh) | 2020-08-28 |
AU2018362008A1 (en) | 2020-04-23 |
BR112020008546A2 (pt) | 2020-10-06 |
JP2021512044A (ja) | 2021-05-13 |
CA3079157A1 (en) | 2019-05-09 |
RU2020117611A (ru) | 2021-12-02 |
KR20200084004A (ko) | 2020-07-09 |
EP3704269B1 (en) | 2023-08-30 |
US20210196831A1 (en) | 2021-07-01 |
EP4123034A1 (en) | 2023-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR114990A1 (es) | Constructos de oligonucleótidos y usos de los mismos | |
RU2487938C2 (ru) | НУКЛЕИНОВАЯ КИСЛОТА ФОРМУЛЫ (I): GlXmGn ИЛИ (II): GlXmGn, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ПРИМЕНЕНИЯ ПРЕЖДЕ ВСЕГО В КАЧЕСТВЕ ИММУНОСТИМУЛЯТОРА/АДЪЮВАНТА | |
MX2020001734A (es) | Derivados de 6-amino-7,9-dihidro-8h-purina-8-ona como agonistas inmunoestimulantes del receptor 7 tipo toll (tlr7). | |
PH12019502333A1 (en) | Targeted compositions | |
MX2020001475A (es) | Derivados de 6-amino-7,9-dihidro-8h-purin-8-ona como agonistas del receptor 7 tipo toll (tlr7) inmunoestimulantes. | |
AU2007280690B2 (en) | Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant | |
Reed et al. | New horizons in adjuvants for vaccine development | |
ES2911034T3 (es) | Estructura y uso de oligonucleótidos 5' fosfato | |
NZ747138A (en) | Targeted nucleic acid conjugate compositions | |
DK2176408T3 (en) | Nucleic acids comprising formula (NuGiXmGnNv) α and derivatives thereof as immunostimulants / adjuvants | |
AU2017245687A1 (en) | Nucleic acid linked to a trivalent glycoconjugate | |
RU2016122168A (ru) | Антисмысловые конъюгаты, направленные на аполипопротеин b | |
BR112012008142A8 (pt) | conjugados de peptídeo/ polietilenoglicol ligados a dissulfeto para a transfecção de ácidos nucleicos | |
PE20152002A1 (es) | Composiciones y metodos para modular la expresion de ttr y vhb | |
BRPI0622298A8 (pt) | Oligorribonucleotídeo para estimular a produção de uma citocina pró-inflamatória, uso do mesmo e composição contendo tal oligorribonucleotídeo | |
AU2017223267B2 (en) | Amino acid and peptide conjugates and conjugation process | |
Das et al. | A peptide nucleic acid–aminosugar conjugate targeting transactivation response element of HIV-1 RNA genome shows a high bioavailability in human cells and strongly inhibits Tat-mediated transactivation of HIV-1 transcription | |
Zhang et al. | Conjugation of chitosan oligosaccharides enhances immune response to porcine circovirus vaccine by activating macrophages | |
CN113950486A (zh) | pHLIP®-介导的免疫刺激化合物的细胞内递送 | |
Tom et al. | Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation | |
TW201639583A (zh) | 具有免疫賦活活性之含有CpG-間隔基-寡核苷酸複合體及其用途 | |
WO2018201058A3 (en) | Sialidase inhibitors and preparation thereof | |
WO2018185252A1 (en) | Nucleic acid conjugates | |
MX2023005138A (es) | Conjugados dirigidos que comprenden arnpi modificado. | |
CA3086690A1 (en) | D-glycero-b-d-heptose 1-phosphate (hmp) conjugates and use for targeted immune modulation |